Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The U.K-. and Germany-based gene therapy start-up Freeline Therapeutics has raised $116 million in series B financing, most of it coming from British life sciences investment company Syncona. Freeline will use the money to develop adeno-associated virus (AAV) gene therapies for hemophilia B, caused by a deficiency in clotting factor IX, and for Fabry disease, caused by a deficiency of a lipid-metabolizing enzyme. Gene therapy clinical trials for those diseases are already under way at competitors Spark Therapeutics and Avrobio.
This article has been sent to the following recipient: